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Anabolic agents: Adjuncts to nutrition support !
Jane Gervasio !
Clarian Health at Methodist Hospital, Indianapolis, Indiana !
Abstract !
Anabolic agents as adjuncts to nutrition support therapy have been used to improve malnutrition 
and establish anabolism. Growth hormone, insulin-like growth factor, and anabolic steroids have 
been studied for their potential to reverse the catabolic process and promote anabolism. This 
paper reviews several anabolic agents and their possible role in nutrition support therapy. !!
The pursuit to halt or suppress the catabolic response to injury or disease has led to the 
investigation and administration of anabolic agents with specialized nutrition support. The 
catabolic response is multifactorial and enhances total body protein breakdown. Progressive loss 
of body protein leads to increased morbidity, impaired immune function, increased infection 
rates, impaired healing, and weakness; catabolic illnesses may eventually result in multiple-organ 
failure.1 !
Protein energy malnutrition is associated with increased morbidity and mortality and is still a 
common problem in hospitalized patients.2 Nutrition support is administered to patients to 
decrease net protein loss. Quantities as high as 2 to 3 g/kg per day of protein have been used in 
attempts to produce an anabolic condition.3 Although nutrition support has improved patient 
outcomes, it has failed to circumvent the catabolic response. Anabolic agents, in conjunction 
with nutrition support, have the potential to improve body composition by maintain- ing or 
enhancing lean body mass (LBM). Recombinant human growth hormone (HGH), insulin-like 
growth factor-1 (IGF-1) and anabolic steroids have been investigated as a means to increase 
protein synthesis and inhibit protein breakdown. !
Growth Hormone !
HGH is an amino acid polypeptide synthesized by the pituitary and secreted from the 
hypothalamus into the bloodstream. HGH is an anabolic agent that attenuates injury-induced 
catabolism, stimulates protein synthesis, reduces adipose tissue, improves humoral and cellular 
systemic host defenses, and increases muscle mass.4,5 Growth hormone’s effect on protein 
metabolism by increasing protein synthesis without affecting protein degradation has enticed 
researchers to investigate its potential use in trauma,5,6 thermally injured,4,7 postoperative,8 
septic,9 and critically ill patients.10,11 !!!
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Critical Care 
Research with HGH in critically ill patients has evolved over 20 years. Early studies reported 
that HGH improved nitrogen retention and protein synthesis, decreased donor site healing time, 
and reduced postoperative fatigue.4,9-11 Unfortunately, these early studies were small in number 
and clinical outcome data were not reported. !
Much of the research with HGH has been in thermally injured and trauma patients to evaluate its 
ability to reverse severe catabolism resulting from the injury. Knox and colleagues7 
retrospectively reviewed 69 thermally injured patients and reported a decreased mortality rate in 
patients receiving HGH compared with a control group (11% vs 37%, p < .03, respectively).7 
Herndon et al,12 in a prospective, double-blind, randomized study, enrolled 40 children between 
the ages of 2 and 18 years, with ≥40% total body surface area (TBSA) and ≥20% TBSA full-
thickness flame or scald burns to receive placebo or 0.1 mg/kg per day HGH throughout hospital 
stay. After 24 patients were enrolled (12 patients receiving placebo and 12 patients receiving 
HGH), no differences were reported between rate of first donor-site healing, IGF-1 levels, or 
adverse events. The institutional review board mandated the study be redirected, and 
subsequently 16 patients were randomized to receive placebo or 0.2 mg/kg per day HGH. 
Patients receiving 0.2 mg/kg per day of HGH demonstrated significantly higher serum IGF-1 
levels (4.8 ± 1.7 U/mL compared with control patients at 1.6 ± 0.4 U/mL; p < .05) and a 
significant decrease in donor-site healing times at first harvest compared with placebo (9.1 ± 0.4 
days vs 7.4 ± 0.6 days, p < .05, respectively) and second harvest (9.0 ± 0.7 days vs 5.7 ± 0.3 
days, p < .05 days, respectively). Length of hospital stay (length of hospital stay/% TBSA) was 
decreased from 0.80 ± 0.10 days per percentage of TBSA in the placebo group to 0.52 ± 0.04 
days per percentage of TBSA burn in the 0.2 mg/kg per day treatment group (p < .05).12 !
Concern arose in November 1997 when the US Food and Drug Administration released a drug 
warning reporting a significantly higher mortality in critically ill patients receiving HGH. This 
drug warning was prompted by 2 parallel studies from Finland and Europe. Takala and 
colleagues13 performed 2 prospective, multicenter, double-blind, randomized, placebo-controlled 
trials involving a total of 532 patients (247 Finnish patients and 285 European patients) who had 
been in an intensive care unit (ICU) for 5 to 7 days and were expected to remain in the ICU for at 
least 10 days. The patients were admitted to the ICU belonging to 1 of 4 diagnostic groups: 
cardiac surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Exclusion 
criteria included patients with cancer, type 1 diabetes mellitus, chronic renal failure, burns, organ 
transplants, acute central nervous system damage, hepatic dysfunction, septic shock, or 
glucocorticoid therapy. Patients received either a daily dose of 0.10 ± 0.02 mg/kg HGH or 
placebo until discharged from the ICU or for a maximum of 21 days. The investigators reported 
that in both studies, the hospitalized mortality rate was higher in the patients who received HGH 
than in those who did not (p < .001). The mortality rate in the Finnish study was 39% in the 
HGH group as compared with 20% in the placebo group and in the European study, 44% in the 
HGH group compared with 18% in the placebo group. The relative risk of death for patients 
receiving HGH was 1.9 in the Finnish study (95% confidence interval, 1.3 to 2.9) and 2.4 in the 
European study (95% confidence interval, 1.6 to 3.5). Increased mortality associated with the 
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treatment group persisted when the data were analyzed according to diagnostic group, Acute 
Physiology and Chronic Health Evaluation (APACHE) II score, and age. Mortality rates were 
similar in men and women. The investigators also reported increased length of ICU and hospital 
days and increased days on mechanical ventilation among the survivors. !
In the European study, most of the deaths occurred in the first 10 days of treatment, whereas in 
the Finnish study, half of the deaths occurred during the first 10 days of treatment and then the 
remainder occurred >3 weeks after enrollment. Main causes of death in both treatment groups 
were multiple-organ failure and septic shock or uncontrolled infections. The predominance of 
these causes of death was particularly marked in the patients receiving HGH. !
The reason for the increased mortality is unclear but several hypotheses have been presented. 
Takala et al13 postulated that with multiple-organ failure, septic shock, and uncontrolled infection 
as major causes of death in the study group, there was a modulation of immune function 
involved. HGH has been reported to augment or inhibit the production of reactive oxygen 
species and proinflammatory cytokines and reduce or increase the susceptibility to endotoxin or 
bacterial challenge in animals. This would suggest that HGH might be either beneficial or 
detrimental in a catabolic patient, depending on the underlying clinical condition. !
Increased blood glucose concentrations are a common adverse effect with HGH. HGH-induced 
hyperglycemia could have resulted in an increase in infections and infectious complications. 
Takala et al13 reported increased blood glucose concentrations in patients receiving HGH. The 
cause of hyperglycemia has been attributed to defective nonoxidative glucose disposal, an 
increase in splanchnic glucose release, and increased peripheral insulin resistance.14 
Hyperglycemia is associated with an increased risk of sepsis, and tightly controlled glucose 
concentrations have been reported to decrease morbidity and mortality in critically ill patients.15 
Insulin resistance induced by HGH could have deprived cells of glucose, leading to energy 
deficit,13 or hyperglycemia from HGH could have increased the potential for infection and sepsis, 
leading to multiple organ dysfunction. Decreased mobilization of glutamine from muscle has 
also been speculated as a reason for the reported increased mortality.13 Decreased mobilization 
would result in less glutamine available for leukocytes and enterocytes and for hepatic 
production of glutathione.16 !
Osterziel and colleagues17 proposed a theory for increased multiple-organ failure in the patients 
receiving HGH. The authors suggest that growth signals to damaged cells may trigger cell death 
in some tissues. Administration of HGH increases concentrations of IGF-1.14 Serum growth 
hormone and IGF-1 concentrations have been associated with increased myocyte apoptosis in 
patients with acromegalic cardiomyopathy.18 Stimulation of the growth hormone and IGF-1 
receptor pathways could trigger apoptotic signals in compromised cells resulting in cellular death 
and ultimately, organ failure. !
In an invited editorial by Demling,19 major differences between the populations were identified 
as the potential reason for the increase in mortality seen in the study by Takala et al.13 In that 
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study, the average age was 60 years and the majority of patients had respiratory failure (95%). 
Less than 10% were trauma patients. Earlier trials with HGH were usually in younger patients, 
and the majority of patients investigated were trauma, burn, and surgical patients. Demling 
proposed the increased mortality in the study by Takala et al13 might have been caused by 
negative hypermetabolic and proinflammatory effects of HGH in the study populations.19 !
Growth hormone causes an initial energy deficit by directly increasing cellular metabolic rate 
and indirectly by increasing plasma catecholamine concentrations, which in turn increase energy 
demand. Demling19 theorized that in patients in whom the systemic inflammatory response is 
activated, there is not a worsening energy deficit or further increased metabolic rate when HGH 
is added. The possibility of sudden energy deficit in the septic, trauma, or thermally injured 
patient is decreased because the systemic inflammatory response has been activated. But in 
patients in whom systemic inflammation is not a component of their disease process, increases in 
mortality may be the result of an energy deficit from HGH.19 !
Whether it is an energy deficit, a combination of factors, or an unidentified process, HGH should 
not be given to critically ill patients. Although thermally injured or trauma patients may be an 
exception, research with growth factors in critical care has been redirected from HGH to 
anabolic steroids. Oxandrolone and other anabolic steroids have become the more popular agents 
of research because of positive findings and less adverse effects. !!
Disease-Related Cachexia 
Administration of HGH and other anabolic agents has been investigated for its effects on 
disease-related cachexia, including cachexia from human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) and cancer. Weight loss and protein malnutrition 
remain significant problems in these populations. Increases in morbidity and mortality are 
attributed to muscle wasting from the disease processes. Quality-of-life issues including a 
parallel decline in energy level, strength, and functional status associated with loss of LBM. 
Nutrition alone has not been sufficient to maintain body weight in the HIV/AIDS and cancer 
patient. Whether because of insufficient intake or malabsorption of nutrition, additional measures 
have been researched and implemented to help restore and maintain LBM.20,21 !
In a study by Mulligan et al,22 6 HIV-positive men with an average weight loss of 19% and 6 
healthy, weight-stable HIV-negative controls were followed on a metabolic ward for 19 days and 
fed a constant diet at a level of energy intake to maintain body weight. After 7 days of a 
pretreatment period, patients were given 0.1 mg/kg per day HGH for 7 days. Both the HIV-
positive and HIV-negative men maintained their weight during the pretreatment phase and 
progressively increased their weight during the treatment phase. Weight gain averaged 2.0 ± 0.3 
kg and 1.6 ± 0.2 kg in the HIV-positive and HIV-negative subjects, respectively. Plasma 
concentrations of IGF-1 increased 3-fold in the HIV-negative subjects and only 2-fold in the 
HIV-positive subjects, but no significant differences were seen in nitrogen retention (4.0 ± 0.2 g/
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day, HIV-positive and 4.0 ± 0.6 g/day, HIV-negative). These results demonstrated HIV-positive 
men were capable of responding to HGH in a manner similar to HIV-negative men. !
Krentz et al23 followed 4 patients with HIV-associated wasting and administered HGH for 3 
months at a dosage of 5 mg every other day. Patients showed improved weight gain and LBM as 
measured by bioelectrical impedance analysis. Three patients receiving 2.5 mg every other day 
did not show any significant improvement in weight or LBM. !
A larger, 3-month, randomized, double-blind, placebo-controlled multicenter study was 
conducted to determine if protein-anabolic effects of HGH could be sustained in a large group of 
patients with HIV-associated wasting.24 A total of 178 patients with >10% weight loss or actual 
body weight <90% of ideal for body size were randomized to receive 0.1 mg/kg per day HGH (n 
= 90) or placebo (n = 88). At completion of the study, patients receiving HGH had sustained 
significant increases in weight and LBM and significantly decreased fat mass. Patients receiving 
a placebo did not have significant changes in weight, LBM, or fat. !
Quality of life and energy level was also evaluated. After the 3-month period of receiving HGH, 
HIV-positive subjects showed an improvement in work output (graded treadmill testing). 
Volitional exhaustion increased significantly in the HGH group compared with placebo (13.2% 
vs 2.5%, respectively). Interestingly, quality of life, as assessed by an HIV-specific questionnaire, 
was not affected by HGH treatments, nor were significant differences reported in days of 
disability and use of ambulatory, hospital, or home care services.24 !
Limited research is available in cancer-related cachexia. Preliminary data from Wolf and 
colleagues25 examined the effect of HGH and insulin administration on protein kinetics in cancer 
patients. Twenty-eight cancer patients received either 0.1 mg/kg per day HGH (n = 6), 0.2 mg/kg 
per day HGH (n = 6), or nothing (n = 16) for 3 days. Patients then underwent measurement of 
baseline protein kinetics followed by a 2-hour euglycemic insulin infusion (1 mU/kg per minute) 
and repeat kinetic measurements. Cancer patients receiving HGH and insulin had significantly 
improved whole-body protein net balance and skeletal muscle protein net balance. !
In a similar study, Berman et al26 investigated the impact of HGH alone and in combination with 
insulin. Patients with malignancies of the upper GI tract were prospectively randomized into 1 of 
3 nutrition support groups after surgery: 10 patients received standard parenteral nutrition (PN), 
10 received PN plus daily injections of HGH, and 10 received daily GH, systemic insulin, and 
PN. Standard PN per 24 hours was 2000 mL (500 mL of 20% lipid solution [Intralipid; Baxter, 
Deerfield, IL] plus 1500 mL amino acids and dextrose solution). HGH was dosed at 0.1 mg/kg 
per day and 1.4 units/kg regular human insulin were added to the PN. Patients receiving insulin 
in the PN also received a bolus of 400 mU/m2 of regular human insulin on day 1, before PN was 
initiated. Patients underwent a protein kinetic radiotracer study on the fifth day after surgery to 
determine whole body and skeletal muscle protein kinetics. Patient’s receiving either HGH or 
HGH plus insulin showed improved skeletal muscle protein net balance and whole body protein 
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net balance compared with PN alone. No significant differences between HGH and HGH with 
insulin were noted. !
A small, short-term study by Tayek and Brasel27 failed to show improved anabolism in 
malnourished cancer patients receiving HGH. Ten cancer patients were given HGH injections for 
3 days (0.125 mg/kg per day). Seven of the 10 patients who were at or above their ideal body 
weight showed improved nitrogen balances from baseline (-1.46 ± 0.99 vs 0.60 ± 1.03 g/day;  
p < .01). Unfortunately, severely malnourished patients (<90% of ideal body weight) did not 
show significant improvement in nitrogen retention. !
Growth hormone administration in chronic dialysis patients causes increased weight gain and 
decreased blood urea nitrogen.28,29 Unfortunately, long-term treatment with HGH in 
malnourished hemodialysis patients failed to show improvement in nutritional or anthropometric 
parameters.30 Nineteen malnourished hemodialysis patients received HGH 0.125 IU/kg 3 times a 
week during the first 4 weeks and HGH 0.25 IU/kg 3 times a week thereafter for a total of 12 
months. IGF-1 concentrations rose significantly from baseline over the first 3 months but 
declined thereafter. Total body fat declined at 3 and 9 months but LBM remained stable. 
Nutritional parameters (serum levels of albumin, prealbumin, transferrin) were not affected, nor 
was blood urea nitrogen.31 !
Intestinal Adaptation/Growth 
Enteral nutrition support is critical for normal intestinal cell growth and function. Failure to 
stimulate intestinal mucosa and submucosa results in atrophy of the gut. Remaining mucosal 
cells exhibit cellular hyperplasia and increase net nutrient transport. This process is termed 
intestinal adaptation.32 !
Growth hormone and IGF-1 are 2 of several peptide growth factors required for normal intestinal 
growth and mucosal repair.32 In patients in whom intestinal adaptation is insufficient, the 
addition of exogenous growth factors has been explored. Early research investigating the 
addition of HGH with or without additional glutamine to the patients with short bowel syndrome 
(SBS) showed improvements in weight gain, increased LBM, and decreased dependence on PN.
33-36 !
Conversely, later research did not confirm these findings. In a 6-week, randomized, double-blind, 
placebo-controlled crossover study, Scolapio et al37 compared the effects of high dose HGH 
(0.14 mg/kg per day), oral glutamine (0.63 g/kg per day), and a high-carbohydrate, low-fat diet 
on gut adaptation in 8 patients with SBS. Patients received 21 days of active treatment or placebo 
and then patients were crossed over. Results showed active treatment transiently increased body 
weight, significantly increased absorption of sodium and potassium, and decreased gastric 
emptying. No differences were seen with the assimilation of macronutrients, stool volumes, and 
morphometry of small bowel mucosa when the patient received active treatment or placebo. !
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Szkudlarek and colleagues38 performed a similar study reporting the same results. In a 
randomized, double-blind, placebo-controlled, crossover study, 8 patients with SBS received 
high-dose HGH (0.12 mg/kg per day, mean) with oral (28 g/day, mean) and parenteral (5.2 g/
day) glutamine for 28 days. Balance studies were performed at baseline and 5 days after the 
treatment was terminated. As with the study by Scolopio et al,37 HGH with glutamine did not 
improve intestinal absorption compared with placebo.38 Further analysis by the same 
investigators reported no changes in body weight or composition. And increases in LBM, 
comparing treatment and baseline periods, was not accompanied by an increase in 24-hour 
urinary creatinine excretion.39 !
Interestingly, Seguy et al40 administered low-dose HGH (0.05 mg/kg per day) to 12 adult, PN- 
dependent patients with SBS in a randomized, double-blind, placebo-controlled, crossover study. 
Patients were on an unrestricted diet. Patients received HGH and placebo for a 3-week period 
separated by a 1-week washout period. Net intestinal absorption of macronutrients was assessed 
using a duplicated diet. Results showed a significant increase in intestinal absorption, body 
weight, LBM, D-xylose absorption, IGF-1 levels, and insulin-like growth factor binding protein 
when patients were treated with HGH. The authors concluded that low-dose HGH significantly 
improved intestinal absorption in PN-dependent SBS patients. Growth hormones role in 
intestinal adaptation is still controversial and further research in needed to determine its dose, 
duration, and appropriateness. !
Insulin-like Growth Factor !
Insulin-like growth factor is an amino acid, single-chained polypeptide synthesized primarily in 
the liver and under growth hormone control. Serum concentrations of IGF-1 usually parallel 
those of HGH. Insulin-like growth factor promotes growth function and has the ability to 
increase protein synthesis and decrease protein degradation. Unlike GH, IGF-1 does not induce 
insulin resistance; therefore, hyperglycemia is avoided. Unfortunately, because of IGF-1 effects 
on carbohydrate metabolism, hypoglycemia is frequently seen with IGF-1 administration.41 !
Critical Care 
As with GH, administration of IGF-1 in the critical care population has been investigated as a 
means to diminish or block the catabolic process, especially in the trauma and thermally injured 
patient. In an earlier, randomized, control trial, Kudsk et al42 studied the effects of IGF-1 and 
aggressive PN on CD4/CD8 ratios in head-injured patients. Fourteen patients admitted into a 
level 1 trauma center with a Glasgow Coma Scale score (GCS) of 4 to 10 within 6 hours of 
admission and requiring no major extracranial surgery (except isolated lower-extremity fracture 
fixation) were randomized to receive a continuous infusion of recombinant IGF-1 (0.01 mg/kg 
per hour) or saline. Both groups received PN advanced to a total protein intake of 2 g/kg per day 
and a maximum nonprotein caloric delivery of 40 kcal/kg per day. Patients receiving IGF-1 
administration showed increased CD4/CD8 ratios and elevated IGF-1 levels. Infusion of IGF-1 
and aggressive early IV nutrition in head-injured patients affected the immunologic response. !
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In a phase II, prospective, open-label, safety and efficacy trial, the effect of IGF-1 and aggressive 
nutrition support on the catabolic state and clinical outcome of head-injured patients was 
investigated.43 Similar to the study by Kudsk and colleagues,42 patients were randomized to 
receive a continuous infusion of IGF-1 (0.1 mg/kg per hour) beginning within 72 hours of injury 
and continuing for 14 days. Nutrition support was provided to a goal of 1.25 times the measured 
energy expenditure. PN was used until bowel sounds returned and gastric residual volumes were 
< 700 mL in 24 hours. Thirty-three patients enrolled in the study. The study demonstrated 
improvements in the IGF-1 treated patients including weight gain despite a significantly higher 
measured energy expenditure and lower calorie intake (p = .02), decreased nitrogen excretion, 
and improved nitrogen balances. Improvements were reported in GCS scores in those patients 
receiving IGF-1. !
In an open-labeled, uncontrolled, prospective study, administration of a single dose of IGF-1 in 
patients with systemic inflammatory response syndrome was studied. Eight patients received 
subcutaneous administration of 40 µg/kg of IGF-1. Blood samples were taken 24 hours before 
and 48 hours after the IGF-1 dose. Results showed IGF-1 levels rose significantly above 
baseline, and peak concentrations were sustained 2 to 5 hours after treatment. No adverse effects 
were observed.44 !
Administration of IGF-1 has also been studied in thermally injured patients. Ten adult patients 
were studied consecutively after receiving saline (pre-treatment), and then IGF-1 combined with 
its principal binding protein IGF-1 binding protein-3 (IGFBP-3) for 5 days. Doses of IGF-1/
IGFBP-3 were delivered as 1, 2, and 4 mg per day. As expected, IGF and IGFBP-3 
concentrations increased but no incremental increases were discovered. No glucose 
abnormalities developed.45 !
Growth hormone and IGF-1 combination therapy used in healthy volunteers increase anabolic 
effects and decrease adverse events,46,47 but the effects were not duplicated in HIV-wasting.48 In 
a randomized, placebo-controlled trial of combination IGF-1 (5 mg subcutaneous twice daily) 
and low-dose HGH (0.34 mg subcutaneous twice daily), a total of 142 patients were randomized 
to receive either active treatment or placebo injections for 12 weeks. Eighty subjects completed 
the 12-week protocol. Weight gain at the end of 3 weeks of active treatment resulted in a 
significantly greater weight gain compared with controls, but this effect was not sustained by the 
end of the study. No significant differences were seen in isokinetic muscle strength, endurance 
testing, or quality of life. Growth hormone and IGF-1 treatment resulted in increased incidences 
of peripheral edema and fluid retention.48 !
Anabolic Steroids !
Testosterone, the primary male hormone produced by the testicles, was first synthesized in a 
laboratory in 1935. Since then, testosterone and its primary derivative, the anabolic-androgenic 
steroids, have received worldwide recognition with mixed reviews. Athletes and bodybuilders 
have taken these drugs to increase muscle mass and to intensify training regimens. And although 
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recognized as “illegal” in competitive sports, anabolic steroids maintain a billion-dollar 
international black market.49 In a more favorable light, testosterone and its analogs have been 
investigated in the malnourished and catabolic patient. !
Testosterone is the body’s naturally occurring anabolic agent with androgenic activity. To mimic 
or enhance this testosterone effect, exogenous testosterone and testosterone analogs are given to 
increase LBM and muscle strength. Early research in trauma and surgical patients investigating 
injectable testosterone and testosterone analogs reported increased nitrogen retention and 
improved nitrogen balances.50,51 Although positive findings were reported in these studies, 
clinicians were skeptical about the use of anabolic steroids, especially in women, because of the 
drugs androgenic complications (edema, lipid abnormalities, and virilizing effects). Additionally, 
with these early studies, clinical outcome data were not reported.50,51 Hence, the use of injectable 
anabolic steroids was not overwhelmingly endorsed. !
More recently developed anabolic agents, including oxandrolone, nandrolone, and 
oxymetholone, have offered a more favorable pharmacotherapeutic approach to catabolism 
because they have 5 to 10 times the anabolic activity of older anabolic steroids and have 
considerably less androgenic effects (Table 1). Oxandrolone and oxymetholone offer the 
advantage of oral administration. Later research has investigated the newer anabolic agents in 
various disease states and medical conditions. !
Critical Care 
Much of the critical care research with anabolic agents is in the thermally injured patient. 
Demling and colleagues52 initially investigated the administration of an anabolic steroid, 
oxandrolone, combined with a high-protein diet (2 g/kg per day) in the recovery phase of 
thermally injured patients. Patients having sustained 30% to 50% deep TBSA burns were 
prospectively, randomized to receive a high-protein diet ±10 mg oxandrolone twice daily. Weight 
gain and muscle function restorations (muscle strength and endurance) were evaluated. Data 
were also compared with results from a retrospective group of burn patients also in the recovery 
phase receiving a high-protein diet of 1.3 to 1.4 g/kg per day. The investigators reported a 
significant increase in weight gain of 14.5 ± 2.5 pounds in the group of patients who received 
oxandrolone (n = 7) compared with the other 2 groups, 7.5 ± 1.7 pounds in the prospective group 
receiving 2 g protein per kg (n = 6) and 4.4 ± 0.8 pounds in the retrospective group receiving 1.3 
to 1.4 g protein per kg (n = 10). In addition, muscle strength (weight machines, pulleys with !
Table 1. Anabolic steriods 
       Androgenic Anabolic Orally 
  Dosage     effects  effects  available 
Testosterone 100 mg/wk    ++++  ++  No 
Nandrolone 50-200 mg × 1 Or in divided does over ++  ++  No 
  a 1- to 2-week period 
Oxandrolone 20 mg/d to 80 mg/d   +  ++++  Yes 
Oxymetholone 10 mg/d to 150 mg/d   +  ++++  Yes 
*Dosages studied 
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weights, and dumbbells for both upper and lower body strengthening) and endurance (stationary 
bike riding, treadmill, and stair stepping) were assessed by a burn therapist and based on 
improvements observed over a 3-week course. Patients who exercised and received oxandrolone 
exceeded the therapist’s expected outlined goals. Patients in the prospective study receiving only 
a high-protein diet reached 95% ± 9% of the outlined goals by 3 weeks, and the retrospective 
group reached 75% ± 12% of the outlined goals. The authors concluded that an anabolic steroid 
combined with increased protein intake significantly increased the rate of restoration of weight 
gain and improved physical therapy recovery. !
Demling53 followed his initial study by prospectively comparing oxandrolone and HGH in 
patients who sustained a severe burn injury. Criteria for entry into the study included deep burns 
over 50% TBSA, at least half requiring grafting, or deep burns over 25% TBSA with comorbid 
factors (eg, age over 60 years, malnutrition, or adult-onset diabetes). Patients were randomized to 
receive HGH at a dose of 0.1 mg/kg per day (n = 20) or oxandrolone 20 mg/day (n = 16), 
beginning between days 7 and 10 postburn and continuing until patients were sufficiently healed 
to be transferred to a rehabilitation center. Data were compared with data from burn patients not 
receiving either agent (n = 24). Results showed a net weight loss of 8 ± 2.1 kg in the control 
group compared with losses of 4 ± 1.8 kg with HGH and 3 ± 1.2 kg with oxandrolone. Net daily 
nitrogen loss was also significantly less in the patients receiving HGH and oxandrolone. A 
significant decrease in complete healing time of a standardized donor site from the control value 
of 14 ± 2 days to 10.3 ± 3 days for HGH and 10 ± 2 days for oxandrolone was also reported. 
Both anabolic agents significantly decreased weight and nitrogen loss and increased healing with 
nearly identical benefits. However, HGH did result in increased incidences of hyperglycemia, 
though therapy did not have to be discontinued. There was a significantly higher percentage of 
diabetic patients in the HGH and oxandrolone group than the control group. No side effects were 
noted with oxandrolone.53 !
Hart and colleagues54 explored the hypothesis that oxandrolone might reverse muscle catabolism 
in cachectic, critically ill pediatric burn patients. Fourteen severely burned children were enrolled 
during a 5-month period in a prospective cohort study. All patients were admitted to the Shriners 
Burn Hospital for Children in Galveston, Texas, at least 1 week after injury. The authors noted a 
prolonged delay in the arrival of these patients to the burn unit for definitive care resulted in 
critically ill children with significant malnutrition. Enteral nutrition (Vivonex TEN; Sandoz 
Nutritional Corp, Minneapolis, MN) was initiated in all patients. Daily caloric intake was given 
at a rate calculated to deliver 1500 kcal/m2 TBSA. Within 48 hours of admission, each patient 
underwent total burn wound excision and grafting. After the first surgical procedure, all patients 
were studied on postoperative day 5 to determine baseline protein metabolism. Net 
phenylalanine balance across the leg and the fractional synthetic rate of skeletal muscle protein 
were measured. When the donor sites healed in 6 to 10 days, patients again underwent another 
excision and grafting procedure. After the second surgical procedure, patients assigned to the 
treatment group received oxandrolone 0.1 mg/kg twice daily for 5 days. A second series of 
protein kinetic studies were performed on postoperative day 5 after the second surgical procedure 
to determine any differences with oxandrolone treatment or time between the drug and control 
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patients. The investigators reported muscle protein net balance decreased in the control group 
(-0.006 ± 0.021) and improved in the treatment group (0.064 ± 0.016; p < .05 vs time control). 
The improvement in the oxandrolone group was associated with increased protein synthesis 
efficiency. Muscle protein breakdown was unchanged.54 !
The investigators followed up with a study seeking to extend their findings to severely burned 
subjects who received early definitive treatment.55 Using a similar design as their previous study, 
32 severely burned children were enrolled in a prospective, randomized trial. No time lapse 
between injury and definitive care was present. As with the first study,54 protein net balance did 
not improve in the placebo group, but a significant improvement was seen in the oxandrolone 
group. Body weights and fat-free mass significantly decreased in the placebo group. No 
significant differences were seen in incidences of sepsis and length of stay between the 
oxandrolone group and the placebo group.55 !
Demling and Orgill56 investigated the effects oxandrolone when given to patients in the initial 
phase of their burn recovery. In a prospective, double-blind, placebo-controlled study, patients 
with 40% and 70% TBSA burns were randomized to receive oxandrolone 20 mg/day (n = 11) or 
a placebo (n = 9) initiated between days 2 and 3 postburn. Patients continued taking the anabolic 
agent or placebo until the degree of wound closure and recovery was sufficient to transfer to an 
acute rehabilitation unit. Enteral nutrition was the primary nutritional route. Protein was 
delivered at 2 g/kg/day to all patients. Net weight loss was 8 ± 3.1 kg in the placebo group 
compared with a loss of 3 ± 1.9 kg in the oxandrolone group (p < .05). Net daily nitrogen loss 
was significantly less in the treatment group (13 ± 4 g, placebo vs 4 ± 1.9 g, oxandrolone;  
p < .05) and healing time (13 ± 3 days, placebo vs 9 ± 2 days, oxandrolone; p < .05). Average 
length of stay before transfer to an acute burn rehabilitation center was 35 ± 9 days for the 
placebo group and 29 ± 8 days for the oxandrolone group. The investigators reported a valid 
comparison of length of stay could not be made between the placebo and oxandrolone because of 
small group size.56 !
Nutrition support and the administration of anabolic steroids have long been investigated in the 
surgical and trauma patient for the preservation of LBM. Early studies investigating the use of 
nandrolone and stanozolol reported improvements in nitrogen balance as a result of decreases in 
nitrogen excretion, but clinical outcome data were not studied.50,51,57 !
Gervasio and colleagues58 investigated oxandrolone administration in multiple trauma patients. 
In a prospective, double-blind, placebo-controlled study, 60 trauma patients were randomized to 
receive oxandrolone 10 mg twice daily (n = 30) or placebo (n = 30) for a maximum of 28 days or 
until discharge if earlier. Patients received enteral nutrition within 48 hours of admission and 
oxandrolone/placebo treatment was started. The 2 groups were similar for demographics and 
enteral nutrition delivery. Measurement of total urinary nitrogen at study entry showed both 
groups to be highly catabolic (oxandrolone 17.2 ± 4.9, placebo 19.1 ± 10.8 g/day, NS). On days 7 
and 10, urinary nitrogen increased in both groups, but there were no significant differences 
between groups. Nitrogen balance was negative throughout the study. Serum prealbumin 
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concentrations increased significantly from baseline but no significant difference was seen 
between the oxandrolone and placebo group. The groups did not differ significantly for length of 
stay (oxandrolone 30.8 ± 17.9 days, placebo 27.0 ± 25.7 days), ICU stay (oxandrolone 17.1 ± 7.8 
days, placebo 15.5 ± 9.7 days) or frequency of pneumonia or sepsis (oxandrolone 48 episodes, 
placebo 43 episodes). The investigators concluded that oxandrolone does not have obvious 
benefit at this dose in nutritional and clinical outcomes during the first 28 days after multiple 
trauma.58 !
Disease-Related Cachexia 
Loss of LBM and decreased energy are common complications of HIV infection, cancer 
cachexia, and respiratory disease (especially chronic obstructive pulmonary disease or chronic 
obstructive pulmonary disease [COPD]). Because of the catabolic processes of these diseases, 
nutrition support alone often fails to maintain LBM in these patients. Recognition of the 
diseases’ catabolic processes and impending complications from malnutrition has prompted 
researchers to investigate the use of anabolic agents. Comparable with research in the critical 
care population, investigators have mainly focused on the newer anabolic agents because of their 
better anabolic and lower androgen profile. !
Most disease-related cachexia research is found in the HIV/AIDS literature. Wasting with HIV is 
attributed to decreased nutrient intake, malabsorption, and abnormalities of metabolism and 
endocrinology associated with HIV infection. HIV-wasting is a major cause of morbidity and 
mortality. Oxandrolone was first evaluated for the treatment of AIDS-associated myopathy and 
wasting by Berger et al59 In a multicenter, double-blind study, 63 HIV-seropositive men with 
>10% loss of body weight were randomized to receive either oxandrolone 5 mg/day, 
oxandrolone 15 mg/day, or placebo for 16 weeks. Patients were excluded for liver disease, a 
history of muscle disease, treatment with an appetite-stimulating agent within 8 weeks of 
enrollment, use of medications know to interact with anabolic steroid, coagulation disorders, 
history of drug abuse, eating disorders, alcoholism, significant psychiatric disorders, chronic 
diarrhea, and chronic fever. Body weight, neuromuscular evaluation, and measures of well-being 
were repeatedly assessed. !
There were no major differences between the groups. All patients were male with a mean age of 
40 years. Eighty-eight percent were Caucasians. Significantly more patients receiving 
oxandrolone 15 mg/day were taking hematopoietic and antidiarrheal medications and had a 
slightly lower mean weight at screening. !
Over the 16-week treatment period, patients receiving oxandrolone 15 mg/day were able to gain 
weight. Patients receiving oxandrolone 5 mg/day maintained their weight, whereas patient 
receiving placebo lost weight. Significantly more patients receiving oxandrolone 15 mg/day 
reported increases in appetite and activity compared with placebo. Oxandrolone was well 
tolerated in all of the patients.59 !
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Earthman et al60 measured changes in body cell mass and quality of life in HIV-infected 
individuals receiving oxandrolone therapy. Twenty-five subjects (24 male, 1 female) between the 
ages of 27 and 56 years received oxandrolone 20 mg/day for 8 weeks. One subject’s oxandrolone 
dosage was reduced to 10 mg/day after 4 weeks. Individuals had been HIV positive for an 
average of 7.2 ± 4.2 years. Fifteen subjects had an AIDS diagnosis and 12 subjects had lost at 
least 10% of the usual body weight in the previous 6 to 12 months. Ten subjects were diagnosed 
with an active opportunistic infection at the time of the study, and all but 3 subjects’ infection 
was resolved by study conclusion. Dietary intake was recorded on 3 nonconsecutive days during 
the week before each testing visit. At the conclusion of the study, individuals receiving 
oxandrolone therapy in conjunction with antiretroviral therapy and nutrition management had a 
significant increase in body weight (2.6 ± 3.0 kg, p < .001) and body cell mass (3.7 ± 3.0 kg,  
p < .001) compared with baseline. Appetite improved (p = .032), and overall quality of life 
improved but did not reach statistical significance (p = .056). !
The addition of oxandrolone to testosterone therapy in combination with resistance exercise has 
been studied. Twenty-four eugonadal men with HIV-associated weight loss received testosterone 
replacement (100 mg/week) to suppress endogenous testosterone production and ensure uniform 
basal testosterone concentrations. Subjects were then randomized to receive oxandrolone 20 mg/
day or placebo in conjunction with resistance training. After 8 weeks, androgen status, LBM, 
nitrogen balance, body weight, and muscle strength were measured. Twenty-two individuals 
completed the study. Both groups demonstrated significant nitrogen retention and increases in 
LBM, weight, and strength compared with baseline, but the gains in the subjects receiving 
oxandrolone were significantly greater. The authors concluded that in eugonadal men with HIV-
associated weight loss, oxandrolone plus a moderately supraphysiologic androgen regimen 
results in increased lean tissue accrual and strength compared with physiologic testosterone 
replacement alone.61 !
Anabolic steroids in combination with resistance training does appear to be more effective than 
pharmacotherapy alone. Asymptomatic HIV-positive men receiving nandrolone (600 mg/wk) for 
12 weeks showed greater improvement in muscle quality (1-repetition maximum, 4.7% to 16% 
improvement) as compared with those men receiving nandrolone in combination with resistance 
training (1-repetition maximum, 51% to 63% increase).62 !
Oxymetholone has also been investigated for the treatment of HIV-wasting. In a double-blind, 
placebo-controlled trial, 89 HIV-positive eugonadal women and men were randomized to receive 
oxymetholone 100 mg/day, oxymetholone 150 mg/day, or placebo for 16 weeks. Both regimens 
of oxymetholone resulted in significantly improved weight gain and body cell mass and 
improved quality of life, appetite, and food intake and reduced weakness (by self-evaluation). Of 
great concern was the reported adverse event of liver-associated toxicity. Forty-three percent of 
patients in the oxymetholone 150 mg/day group, 25% of patients in the oxymetholone 100 mg/
day group, and 8% in the placebo group had a >5 times baseline increase for alanine amino 
transferase, aspartate aminotransferase, and 𝛾-glutamyltransferase.63 !
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Research with anabolic steroids in other disease-related cachexia has been performed. Weight 
restoration, increases in LBM, and anthropometric measurements of arm and thigh 
circumference have been demonstrated with anabolic steroids in patients with COPD.64-66 The 
administration of oxandrolone 20 mg/day for 30 days helped strengthen respiratory musculature 
in individuals with tetraplegia and ventilatory insufficiency.67 Preliminary research investigating 
improvements in wound healing has been reported with oxandrolone.68 Nandrolone decanoate 
implementation in patients receiving chronic dialysis improved LBM, increased dry weight, and 
improved visceral markers.69-70 !
Nandrolone decanoate was investigated as a pharmacotherapeutic agent to improve nutritional 
status in patients after esophageal resection for carcinoma. Forty patients were randomized to 
receive 50 mg nandrolone (n = 19) or placebo (n = 21) injections for 5 doses over 3 months. 
Treatment started 1 month after surgery. Measurements of body weight, midarm muscle 
circumference, and appetite were taken over a 6-month period. Nutrition interventions included 
dietary advice and esophageal dilatation if necessary. No statistical differences were reported 
with any measurable parameter between the steroid treatment group and the placebo group. The 
authors noted an increased dose schedule over a longer period of time might have produced a 
significant response.71 !
Higher doses of oxandrolone have also been investigated. Mendelhall and colleagues72 evaluated 
the efficacy of oxandrolone 80 mg/day in combination with an enteral food supplement in 273 
male patients with severe alcoholic hepatitis. Patients received 80 mg oxandrolone or placebo for 
30 days followed by 60 days of reduced dose (40 mg) oxandrolone or placebo. On an intention-
to-treat basis, only minimal changes in mortality were observed and no significant improvement 
was observed with severe malnutrition. Interestingly, in patients with moderate malnutrition, 
mortality at 1 month was less in patients receiving oxandrolone (9.4%) compared with patients 
receiving placebo (20.9%). The benefit was maintained between these groups at 6 months, with 
the oxandrolone group survival at 79.7% and placebo at 62.7% (p < .05). Significant 
improvements in both the severity of the liver injury (p < .05) and malnutrition (p < .05) were 
also reported.72 !
The investigators compared their results from a nearly identical population treated with 
oxandrolone but not given an enteral food supplement. Patients were stratified according to 
caloric intake, with adequate caloric intake defined as 2500 kcal/ day. No improvement in 
survival was seen in patients with severe malnutrition receiving oxandrolone, but the 
investigators did report that adequate caloric intake was associated with 19% mortality, whereas 
patients with inadequate intake exhibited 51% mortality (p < .05). Patients with moderate 
malnutrition meeting their defined caloric intake and receiving oxandrolone reported reduced 6-
month mortality (4% oxandrolone vs 28% placebo). Patients with moderate malnutrition and 
inadequate caloric intake showed no decline in mortality (30% oxandrolone vs 33% placebo).72 !
The effect of anabolic steroids in differing patient populations continues to be researched. Age-
related anorexia and patients with cardiomyopathies may benefit with the addition of an anabolic 
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steroid.73,74 Although positive effects have been reported, the use of anabolic steroids in disease-
related cachexia still needs to be investigated. Long-term safety from anabolic steroids in 
disease-related cachexia is unclear. Most clinical studies using anabolic steroids used short-term 
administration. No clinical study to date has reported safety data past 6 months. Anabolic steroid 
abuse has been associated with hepatic adenomas and psychotic symptoms.75,76 Clinical research 
is still warranted, and long-term safety is needed. !
Conclusion !
Patients with malnutrition or severe catabolism are at risk for increased morbidity and mortality. 
The implementation of nutrition support has aided the clinician in improving patient care. When 
nutrition support is not enough, the administration of anabolic agents may be warranted. In 
patients with catabolic and disease-wasting medical conditions, anabolic agents including HGH, 
IGF-1, and anabolic steroids may improve nitrogen retention, increase energy and strength, and 
enhance quality of life. Conversely, in the wrong patient population, anabolic agents, particularly 
HGH, may be detrimental. Continued research investigating anabolic agents is necessary to help 
define appropriateness of the pharmacotherapy and improve the patient’s clinical outcome. !
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